News

Does the 23andMe Acquisition Make Regeneron a Buy Now?
Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...
Regeneron to buy 23andMe out of bankruptcy for $256 million
Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...
Medindia on MSN7h
Regeneron Acquires 23andMe in (Dollar) 256M Deal
Regeneron acquires 23andMe's genetics services for (Dollar) 256 million * Customer privacy safeguards will remain in place ...
Drugmaker Regeneron to acquire 23andMe out of bankruptcy
The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...
Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Pharmabiz8h
Predictive Oncology breakthrough coincides with Regeneron Pharma’s acquisition of 23andMe for $256 million: Artificial intelligence meets genomics
Pittsburgh, Pennsylvania Saturday, May 24, 2025, 15:00 Hrs [IST] ...
Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.